palytoxin

(redirected from PTX)
Also found in: Dictionary, Acronyms, Encyclopedia, Wikipedia.

palytoxin

(păl′ə-tŏk′sĭn)
n.
A powerful toxin that occurs in corals of the genus Palythoa of the South Pacific and disrupts the flow of ions across cell membranes. It is rapidly fatal to humans in very small doses and is one of the most complex naturally occurring substances.

palytoxin

(păl″ĭ-tŏk′sĭn) [Fr. Paly(thoa), the genus name of a coral + ″],

PTX

A potent toxin produced by microscopic marine algae that grow on coral. It destroys blood cells, alters cardiac conduction, and damages nerves. Intoxication with PTX can result in bleeding, weakness, blood vessel constriction, ventricular fibrillation, and death.
References in periodicals archive ?
2% PTX) could achieve remarkably higher blood concentration and systemic exposure of PTX in rats, while the retention of PTX was significantly improved.
The Zilver PTX is specifically designed and CE Mark approved to treat PAD affecting the main blood vessel in the thigh, the superficial femoral artery (SFA).
The major PTX component detected was PTX2 SA in both species, with levels generally about 10 times greater than the other forms of PTX.
The decrease in PTH concentration after L-PTX contrasted with the postoperative outcome of the 5 patients with insufficient PTX (Table 1).
The disease Zilver PTX targets, peripheral arterial disease (PAD), is one of the fastest-growing and most pervasive diseases of our time, affecting an estimated 8-12 million Americans each year.
Eight out of ten patients treated with Zilver PTX still had open arteries (primary patency) after one year1.
Dimethyl sulfoxide (DMSO), fetal bovine serum (FBS), 3,3,5,5 tetramethylbenzidine (TMB), PTX and anti-human beta ([beta])-actin antibody were purchased from Sigma-Aldrich (USA).
Cook Medical's Zilver PTX is a drug-coated stent that is used to reopen a long thigh artery, located above the knee (the femoropopliteal artery), narrowed or blocked due to PAD.
Previously unreleased three-year data from the Zilver PTX Randomized Controlled Trial of Paclitaxel-Eluting Stents for Femoropopliteal Disease indicate that Cook Medical's paclitaxel-eluting peripheral vascular stent demonstrated 83.
Food and Drug Administration ("FDA") to market and sell the proprietary Zilver[R] PTX[R] drug-eluting peripheral stent, adding the United States to the list of over 50 markets, including the European Union and Japan, where Zilver PTX is approved for sale.